Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) Gross Profit: 2014-2024

Historic Gross Profit for Voyager Therapeutics (VYGR) over the last 11 years, with Dec 2024 value amounting to $80.0 million.

  • Voyager Therapeutics' Gross Profit fell 45.59% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.4 million, marking a year-over-year decrease of 80.84%. This contributed to the annual value of $80.0 million for FY2024, which is 68.00% down from last year.
  • Per Voyager Therapeutics' latest filing, its Gross Profit stood at $80.0 million for FY2024, which was down 68.00% from $250.0 million recorded in FY2023.
  • Voyager Therapeutics' 5-year Gross Profit high stood at $250.0 million for FY2023, and its period low was $37.4 million during FY2021.
  • For the 3-year period, Voyager Therapeutics' Gross Profit averaged around $123.6 million, with its median value being $80.0 million (2024).
  • As far as peak fluctuations go, Voyager Therapeutics' Gross Profit tumbled by 78.14% in 2021, and later spiked by 511.16% in 2023.
  • Yearly analysis of 5 years shows Voyager Therapeutics' Gross Profit stood at $171.1 million in 2020, then crashed by 78.14% to $37.4 million in 2021, then climbed by 9.33% to $40.9 million in 2022, then skyrocketed by 511.16% to $250.0 million in 2023, then slumped by 68.00% to $80.0 million in 2024.